Nuvation Bio (NYSE:NUVB) was upgraded by analysts at UBS Group AG to a "hold" rating.
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib [Yahoo! Finance]Yahoo! Finance
- A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NYSE:NUVB) had its price target lowered by analysts at HC Wainwright from $18.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
- Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio says preliminary Q4 and FY25 IBTROZI net product revenue was $15.7M and $24.7M [Seeking Alpha]Seeking Alpha
NUVB
Earnings
- 11/3/25 - Beat
NUVB
Sec Filings
- 1/12/26 - Form 8-K
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- NUVB's page on the SEC website